


IFW



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99-383-B1)

In re application of:

John W. Belmont et al.

Serial No.: 10/803,738

Filing Date: March 18, 2004

For: Phosphatases Which Activate Map
Kinase Pathways

Examiner: Unassigned

Group Art Unit: 1651

Confirmation No.: 8046

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,


1. We are transmitting herewith the attached:
 - a) Fourth Supplemental Information Disclosure Statement;
 - b) U.S. PTO 1449 Form with a copy of 50 references; and
 - c) Return Receipt Postcard.
2. With respect to fees:
 - a) No fee is required.
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in a box addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 6 day of October, 2005.

Respectfully submitted,

Date:

Oct. 6, 2005


Emily Miao
Registration No. 35,285



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99-383-B1)

In Application of:

John W. Belmont et al.

Serial No.: 10/803,738

Filing Date: March 18, 2004

For: Phosphatases Which Activate Map
Kinase Pathways

Examiner: Unassigned

Group Art Unit: 1651

Confirmation No.: 8046

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449, copies¹ of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

1. "Gene Expression Technology," *Methods in Enzymology*, D. Goeddel (Ed.) Vol. 185, pages v-ix
2. A. Bradley, "Production and analysis of chimeric mice," pers. comm., and in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, Ed. (IRL Press, Oxford, 1987, pp. 113-152)

¹To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to undersigned.

3. A.J. Flint, et al., "Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases," *Proc. Natl. Acad. Sci.*, Vol. 94, pp. 1680-85 (1997)
4. A.J. Garton, et al., "Identification of p130^{cas} as a Substrate for the Cytosolic Protein Tyrosine Phosphatase PTP-PEST," *Mol. Cell Biol.*, Vol. 16, pp. 6408-6418 (1996)
5. Adams et al., "The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice," *Nature*, Vol. 318, pp. 533-38 (1985)
6. Adams et al., "Tyrosine Kinase and c-Jun NH₂-Terminal Kinase Mediate Hypertrophic Responses to Prostaglandin F_{2α} in Cultured Neonatal Rat Ventricular Myocytes," *Circ. Res.*, Vol. No. 83, No. 2, pp. 167-178 (1998)
7. Alexander et al., "Expression of the c-myc Oncogene under Control of an Immunoglobulin Enhancer in Eμ-myc Transgenic Mice," *Mol. Cell. Biol.*, Vol. 7, pp. 1436-44 (1987)
8. Needleman and Wunsch, "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," *J. Mol. Biol.*, Vol. 48, pp. 443-53 (1970)
9. Altschul et al., "Basic Local Alignment Search Tool," *J. Mol. Biol.*, Vol. 215, pp. 403-410 (1990)
10. Baracos et al., "Stimulation of Muscle Protein Degradation and Prostaglandin E₂ Release by Leukocytic Pyrogen (Interleukin-1), The New England Journal of Medicine, Vol. 308, No. 10, pp. 553-558 (1983)
11. Bernoist and Chambon, "In vivo sequence requirements of the SV40 early promoter region," *Nature*, Vol. 290, pp. 304-10 (1981)
12. Beutler et al., "Recombinant Interleukin 1 Suppresses Lipoprotein Lipase Activity in 3T3-L1 Cells," *J. Immunol.*, Vol. 135, pp. 3969 (1985)
13. Bolton et al., "A General Method for the Isolation of RNA Complementary to DNA," *Proc. Natl. Acad. Sci. U.S.A.*, Vol. 48, pp. 1390 (1962)
14. Brahn et al., "Effects of Tumor Necrosis Factor Alpha (TNF-α) on Collagen Arthritis," *Lymphokine and Cytokine Research*, Vol. 11, pp. 253-256 (1992)
15. Brinster et al., "Regulation of metallothionein-tymidine kinase fusion plasmids injected into mouse eggs," *Nature*, Vol. 296, pp. 39-42 (1982)
16. Brodeur et al., "Mouse-Human Myeloma partners for the Production of Heterohybridomas," *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker 1987).
17. Bruggermann et al., "Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals," *Year in Immunol.*, Vol. 7, pp. 33-40 (1993)

18. Carrtillo et al., "The Multiple Sequence Alignment Problem in Biology," *SIAM J. Applied Math.*, Vol. 48, pp. 1073-1082 (1988)
19. Chandrasekhar et al., "Arthritic Induced by Interleukin-1 Is Dependent on the Site and Frequency of Intraarticular Injection," *Clinical Immunol Immunopathol.*, Vol. 55, pp. 382-400 (1990)
20. Chien et al., "The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest," *Proc. Natl. Acad. Sci. U.S.A.*, Vol. 88, pp. 9578-832 (1991)
21. Clouse et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression In A Chronically Infected Human T Cell Clone," *J. Immunol.*, Vol. 142, pp. 431-438 (1989)
22. "Computational Molecular Biology – Sources and Methods for Sequence Analysis," A Lesk, Ed. (Oxford University Press 1988)
23. "Methods in Molecular Biology 24 - Computer Analysis of Sequence Data," Part 1, *Methods in Molecular Biology*, Vol. 24 (1994), A.M. Griffin et al., Ed., pages v – xi
24. D.C.I. Goberdhan and C. Wilson, "JNK, cytoskeletal regulator and stress response kinase? A *Drosophila* perspective," *BioEssays*, Vol. 20, pp. 1009-1019 (1998)
25. DeBoer et al., "The *tac* promoter: A functional hybrid derived from the *trp* and *lac* promoters," *Proc. Natl. Acad. Sci. U.S.A.*, Vol. 80, pp. 21-25 (1983)
26. Devereux et al., "A comprehensive set of sequence analysis programs for the VAX," *Nuc. Acids Res.*, Vol. 12, pp. 387-395 (1984)
27. Doetschman et al., "Targetted correction of a mutant HPRT gene in mouse embryonic stem cells," *Nature*, Vol. 330, pp. 576-78 (1987)
28. Doetschman et al., "Targeted mutation of the *Hprt* gene in mouse embryonic stem cells," *Proc. Natl. Acad. Sci. U.S.A.*, Vol. 85, pp. 8583-87 (1988)
29. C. Lang et al., "Tumor Necrosis Factor Impairs Insulin Action on Peripheral Glucose Disposal and Jopathic Glucose Output," *Endocrinol.*, Vol. 130, pp. 43-52 (1994)
30. D. Szalkowski et al., "Antidiabetic Thiazolidinediones Block the Inhibitory Effect of Tumor Necrosis Factor- α on Differentiation, Insulin-Stimulated Glucose Uptake, and Gene Expression in 3T3-L1 Cells," *Endocrinol.*, Vol 136, pp. 1474-1481 (1995)
31. Engels et al., "Gene Synthesis," *Angew. Chem. Intl. Ed.*, Vol. 28, pp. 716-34 (1989)
32. Firestein et al., "Stromelysin and Tissue Inhibitor of Metalloproteinases Gene Expression in Rheumatoid Arthritis Synovium," *Am. J. Pathol.*, Vol. 140, pp. 1309-1314 (1992)

33. Folks et al., "Susceptibility of Normal Human Lymphocytes to Infection with HTLV-III/LAV," *J. Immunol.*, Vol. 136, pp. 4049-4053 (1986)
34. Grosschedl et al., "Introduction of a μ Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody," *Cell*, Vol. 38, pp. 647-58 (1984)
35. Hammer et al., "Diversity of Alpha-Fetoprotein Gene Expression in Mice is Generated by a Combination of Separate Enhancer Elements," *Science*, Vol. 235, pp. 53-58 (1987)
36. Hefti, "Neurotrophic Factor Therapy for Nervous System Degenerative Diseases," *J. Neurobiology*, Vol. 25, pp. 1418-35 (1994)
37. Henikoff et al., "Amino acid substitution matrices from protein blocks," *Proc. Natl. Acad. Sci. USA*, Vol. 89, pp. 10915-19 (1992)
38. Hoogenboom et al., "By-passing Immunisation – Human Antibodies from Synthetic Repertoires of Germline V_H Gene Segments Rearranged *in Vitro*," *J. Mol. Biol.*, Vol. 227, pp. 381-388 (1992)
39. Houghten et al., "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids," *Proc Natl Acad. Sci. USA*, Vol. 82, pp. 5131-5135 (1985)
40. J. Barth and R. Ivarie, "Polyvinyl Alcohol Enhances Detection of Low Abundance Transcripts in Early Stage Quail Embryos in a Nonradioactive Whole Mount *In Situ* Hybridization Technique," *Biotechniques*, Vol. 17, pp. 324-326 (1994)
41. J.M. Denu, J. A. Stuckey, M.A. Saper, J.E. Dixon, "Form and Function in Protein Dephosphorylation," *Cell*, Vol. 87, pp. 361-364 (1996)
42. Jakobovits, et al., "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production," *Proc. Natl. Acad. Sci. U.S.A.*, Vol. 90, pp. 2551-55 (1993)
43. Jones, et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature*, Vol. 321, pp. 522-25 (1986)
44. Kelsey et al., "Species- and tissue-specific expression of human α_1 -antitrypsin in transgenic mice," *Genes and Devel.*, Vol. 1, pp. 161-71 (1987)
45. Kitts et al., "A method for Producing Recombinant Baculovirus Expression Vectors at High Frequency," *Biotechniques*, Vol. 14, pp. 810-17 (1993)
46. Kohler, et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," *Nature*, Vol. 256, pp. 495-97 (1975)
47. Kollias et al., "Regulated Expression of Human γ -, β -, and Hybrid $\gamma\beta$ -Globin Genes in Transgenic Mice: Manipulation of the Developmental Expression Patterns," *Cell*, Vol.

46, pp. 89-94 (1986)

48. Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies," *J. Immunol.*, Vol. 133, pp. 3001 (1984)
49. Krumlauf et al., "Development Regulation of α -Fetoprotein Genes in Transgenic Mice" *Mol. Cell. Biol.*, Vol. 5, pp. 1639-48 (1985)
50. Kucherlapati, "Homologous Recombination in Mammalian Somatic Cells" *Prog. in Nucl. Acid Res. and Mol. Biol.*, Vol. 36, pp. 301-11 (1989)

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.


The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Dated: Oct. 6, 2005

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, Illinois 60606
Telephone : (312) 913-0001
Facsimile: (312) 913-0002

Respectfully submitted,



Emily Miao
Registration No. 35,285

FORM PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

99,383-B1

10/803,738

(Rev. 2-82)

FOURTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

John W. Belmont et al.

Filing Date:

March 18, 2004

Group:

1645

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

1.	"Gene Expression Technology," <i>Methods in Enzymology</i> , D. Goeddel (Ed.) Vol. 185, pages v-ix
2.	A. Bradley, "Production and analysis of chimeric mice," pers. comm., and in <i>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</i> , E.J. Robertson, Ed. (IRL Press. Oxford, 1987, pp. 113-152)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99,383-B1

Serial No.

10/803,738

**FOURTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

John W. Belmont et al.

Filing Date:

March 18, 2004

Group:

1645

3.	A.J. Flint, et al., "Development of substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases," <i>Proc. Natl. Acad. Sci.</i> , Vol. 94, pp. 1680-85 (1997)
4.	A.J. Garton, et al., "Identification of p130 ^{cas} as a Substrate for the Cytosolic Protein Tyrosine Phosphatase PTP-PEST," <i>Mol. Cell Biol.</i> , Vol. 16, pp. 6408-6418 (1996)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

5.	Adams et al., "The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice," <i>Nature</i> , Vol. 318, pp. 533-38 (1985)
6.	Adams et al., "Tyrosine Kinase and c-Jun NH ₂ -Terminal Kinase Mediate Hypertrophic Responses to Prostaglandin F _{2α} in Cultured Neonatal Rat Ventricular Myocytes," <i>Circ. Res.</i> , Vol. No. 83, No. 2, pp. 167-178 (1998)
7.	Alexander et al., "Expression of the c-myc Oncogene under Control of an Immunoglobulin Enhancer in Eμ-myc Transgenic Mice," <i>Mol. Cell. Biol.</i> , Vol. 7, pp. 1436-44 (1987)
8.	Needleman and Wunsch, "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," <i>J. Mol. Biol.</i> , Vol. 48, pp. 443-53 (1970)
9.	Altschul et al., "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> , Vol. 215, pp. 403-410 (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99,383-B1

Serial No.

10/803,738

**FOURTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

John W. Belmont et al.

Filing Date:

March 18, 2004

Group:

1645

10.	Baracos et al., "Stimulation of Muscle Protein Degradation and Prostaglandin E ₂ Release by Leukocytic Pyrogen (Interleukin-1), The New England Journal of Medicine, Vol. 308, No. 10, pp. 553-558 (1983)
11.	Bernoist and Chambon, "In vivo sequence requirements of the SV40 early promoter region," <i>Nature</i> , Vol. 290, pp. 304-10 (1981)
12.	Beutler et al., "Recombinant Interleukin 1 Suppresses Lipoprotein Lipase Activity in 3T3-L1 Cells," <i>J. Immunol.</i> , Vol. 135, pp. 3969 (1985)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

13.	Bolton et al., "A General Method for the Isolation of RNA Complementary to DNA," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 48, pp. 1390 (1962)
14.	Brahn et al., "Effects of Tumor Necrosis Factor Alpha (TNF- α) on Collagen Arthritis," <i>Lymphokine and Cytokine Research</i> , Vol. 11, pp. 253-256 (1992)
15.	Brinster et al., "Regulation of metallothionein-tymidine kinase fusion plasmids injected into mouse eggs," <i>Nature</i> , Vol. 296, pp. 39-42 (1982)
16.	Brodeur et al., "Mouse-Human Myeloma partners for the Production of Heterohybridomas," <i>Monoclonal Antibody Production Techniques and Applications</i> , pp. 51-63 (Marcel Dekker 1987).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99,383-B1

Serial No.

10/803,738

**FOURTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

John W. Belmont et al.

Filing Date:

March 18, 2004

Group:

1645

17.	Bruggermann et al., "Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals," <i>Year in Immunol.</i> , Vol. 7, pp. 33-40 (1993)
18.	Carrillo et al., "The Multiple Sequence Alignment Problem in Biology," <i>SIAM J. Applied Math.</i> , Vol. 48, pp. 1073-1082 (1988)
19.	Chandrasekhar et al., "Arthritic Induced by Interleukin-1 Is Dependent on the Site and Frequency of Intraarticular Injection," <i>Clinical Immunol Immunopathol.</i> , Vol. 55, pp. 382-400 (1990)
20.	Chien et al., "The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 88, pp. 9578-832 (1991)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

21.	Clouse et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression In A Chronically Infected Human T Cell Clone," <i>J. Immunol.</i> , Vol. 142, pp. 431-438 (1989)
22.	"Computational Molecular Biology - Sources and Methods for Sequence Analysis," A. Lesk, Ed. (Oxford University Press 1988)
23.	"Methods in Molecular Biology 24 - Computer Analysis of Sequence Data," Part 1, <i>Methods in Molecular Biology</i> , Vol. 24 (1994), A.M. Griffin, et al, Ed., pages v-xi.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99,383-B1

Serial No.

10/803,738

**FOURTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

John W. Belmont et al.

Filing Date:

March 18, 2004

Group:

1645

24.	D.C.I. Goberdhan and C. Wilson, "JNK, cytoskeletal regulator and stress response kinase? A <i>Drosophila</i> perspective," <i>BioEssays</i> , Vol. 20, pp. 1009-1019 (1998)
25.	DeBoer et al., "The <i>tac</i> promoter: A functional hybrid derived from the <i>trp</i> and <i>lac</i> promoters," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 80, pp. 21-25 (1983)
26.	Devereux et al., "A comprehensive set of sequence analysis programs for the VAX," <i>Nuc. Acids Res.</i> , Vol. 12, pp. 387-395 (1984)
27.	Doetschman et al., "Targetted correction of a mutant HPRT gene in mouse embryonic stem cells," <i>Nature</i> , Vol. 330, pp. 576-78 (1987)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

28.	Doetschman et al., "Targeted mutation of the <i>Hprt</i> gene in mouse embryonic stem cells," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 85, pp. 8583-87 (1988)
29.	C. Lang et al., "Tumor Necrosis Factor Impairs Insulin Action on Peripheral Glucose Disposal and Hepatic Glucose Output," <i>Endocrinol.</i> , Vol. 130, pp. 43-52 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99,383-B1

Serial No.

10/803,738

**FOURTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

John W. Belmont et al.

Filing Date:

March 18, 2004

Group:

1645

30.	D. Szalkowski et al., "Antidiabetic Thiazolidinediones Block the Inhibitory Effect of Tumor Necrosis Factor- α on Differentiation, Insulin-Stimulated Glucose Uptake, and Gene Expression in 3T3-L1 Cells," <i>Endocrinol.</i> , Vol. 136, pp. 1474-1481 (1995)
31.	Engels et al., "Gene Synthesis," <i>Angew. Chem. Intl. Ed.</i> , Vol. 28, pp. 716-34 (1989)
32.	Firestein et al., "Stromelysin and Tissue Inhibitor of Metalloproteinases Gene Expression in Rheumatoid Arthritis Synovium," <i>Am. J. Pathol.</i> , Vol. 140, pp. 1309-1314 (1992)
33.	Folks et al., "Susceptibility of Normal Human Lymphocytes to Infection with HTLV-III/LAV," <i>J. Immunol.</i> , Vol. 136, pp. 4049-4053 (1986)
34.	Grosschedl et al., "Introduction of a μ Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody," <i>Cell</i> , Vol. 38, pp. 647-58 (1984)
35.	Hammer et al., "Diversity of Alpha-Fetoprotein Gene Expression in Mice is Generated by a Combination of Separate Enhancer Elements," <i>Science</i> , Vol. 235, pp. 53-58 (1987)
36.	Hefti, "Neurotrophic Factor Therapy for Nervous System Degenerative Diseases," <i>J. Neurobiology</i> , Vol. 25, pp. 1418-35 (1994)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

37.	Doetschman et al., "Targeted mutation of the <i>Hprt</i> gene in mouse embryonic stem cells," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 85, pp. 8583-87 (1988)
38.	Hoogenboom et al., "By-passing Immunisation - Human Antibodies from Synthetic Repertoires of Germline V_H Gene Segments Rearranged <i>in Vitro</i> ," <i>J. Mol. Biol.</i> , Vol. 227, pp. 381-388 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99,383-B1

Serial No.

10/803,738

**FOURTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

John W. Belmont et al.

Filing Date:

March 18, 2004

Group:

1645

39.	Houghten et al., "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids," <i>Proc Natl Acad. Sci. USA</i> , Vol. 82, pp. 5131-5135 (1985)
40.	J. Barth and R. Ivarie, "Polyvinyl Alcohol Enhances Detection of Low Abundance Transcripts in Early Stage Quail Embryos in a Nonradioactive Whole Mount <i>In Situ</i> Hybridization Technique," <i>Biotechniques</i> , Vol. 17, pp. 324-326 (1994)
41.	J.M. Denu, J. A. Stuckey, M.A. Saper, J.E. Dixon, "Form and Function in Protein Dephosphorylation," <i>Cell</i> , Vol. 87, pp. 361-364 (1996)
42.	Jakobovits, et al., "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 90, pp. 2551-55 (1993)
43.	Jones, et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> , Vol. 321, pp. 522-25 (1986)
44.	Kelsey et al., "Species- and tissue-specific expression of human α_1 -antitrypsin in transgenic mice," <i>Genes and Devel.</i> , Vol. 1, pp. 161-71 (1987)
45.	Kitts et al., "A method for Producing Recombinant Baculovirus Expression Vectors at High Frequency," <i>Biotechniques</i> , Vol. 14, pp. 810-17 (1993)
46.	Kohler, et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , Vol. 256, pp. 495-97 (1975)
47.	Kollias et al., "Regulated Expression of Human γ -, β -, and Hybrid $\gamma\beta$ -Globin Genes in Transgenic Mice: Manipulation of the Developmental Expression Patterns," <i>Cell</i> , Vol. 46, pp. 89-94 (1986)
48.	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies," <i>J. Immunol.</i> , Vol. 133, pp. 3001 (1984)
49.	Krumlauf et al., "Development Regulation of α -Fetoprotein Genes in Transgenic Mice" <i>Mol. Cell. Biol.</i> , Vol. 5, pp. 1639-48 (1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

99,383-B1

Serial No.

10/803,738

**FOURTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

John W. Belmont et al.

Filing Date:

March 18, 2004

Group:

1645

50.

Kucherlapati, "Homologous Recombination in Mammalian Somatic Cells" *Prog. in Nucl. Acid Res. and Mol. Biol.*, Vol. 36, pp. 301-11 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.